Lilly Touts Its R&D Reorganization And Pipeline Prospects, But A Looming Patent Cliff And Risky Bets Take Center Stage
Executive Summary
John Lechleiter faced a tough crowd on Dec. 10: three months after announcing a reorganization of Eli Lilly's R&D apparatus and global cutbacks, the drug maker's CEO came to New York to explain to Wall Street analysts how he planned to cope with a massive loss of revenue due to begin in just two years as patents expire on several best-selling medicines
You may also be interested in...
Deals Of The Week: GSK/Intercell, Novo Nordisk/ZymoGenetics, Lilly/Isis ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/. Also, check out the candidates for the Deals of the Year competition at the blog and cast your vote.
Effient Review Delayed More By Management Issues Than Clinical Disputes
Review management issues, more than unresolved clinical debates, are what produced FDA's lengthy and overdue review of Lilly/Daiichi Sankyo's antiplatelet agent Effient (prasugrel), FDA review documents indicate
Lilly Sings A New Tune: Chorus Unit Brings High Efficiency Note To Early R&D
Lilly's independently operating Chorus drug development unit has created a means to mitigate the risk of drug development by conducting small-scale, targeted experiments separate from the larger R&D organization